Tesofensine (NS-2330): The Complete Guide

Overview

Tesofensine was first synthesized by NeuroSearch A/S, a Copenhagen-based neuroscience company, as part of a program targeting neurodegenerative diseases. The compound was designated NS-2330 and entered clinical development in the late 1990s for Parkinson's disease and Alzheimer's disease, where its triple monoamine reuptake inhibition was hypothesized to improve dopaminergic and cholinergic neurotransmission (Hauser et al., 2007).

During Phase II trials for Parkinson's disease, investigators noticed that patients receiving tesofensine experienced significant and unexpected weight loss. This observation prompted NeuroSearch to pivot the compound's development toward obesity — a decision that led to the landmark TIPO-1 (Tesofensine In the treatment of Patients with Obesity) trial, published in The Lancet in 2008. The results were remarkable: at the 1.0 mg dose, subjects lost an average of 12.8% of body weight over 24 weeks, compared to just 2.0% in the placebo group (Astrup et al., 2008).

These Phase II results positioned tesofensine as potentially the most effective oral weight-loss drug ever tested in a rigorous clinical trial. However, the same trial revealed dose-dependent increases in heart rate and blood pressure — cardiovascular signals that raised serious safety concerns and complicated regulatory prospects. The FDA and EMA require anti-obesity drugs to demonstrate cardiovascular safety, and tesofensine's hemodynamic profile became a significant barrier to advancement through Western regulatory pathways (Astrup et al., 2008).

NeuroSearch ultimately abandoned obesity development in 2011 due to financial difficulties. The rights were subsequently acquired by Saniona (a Danish biotech spun off from NeuroSearch) and Medix (a Mexican pharmaceutical company), which have continued development. Medix has advanced tesofensine through Phase III clinical trials in Mexico, where it is being studied as a fixed-dose combination with the beta-3 adrenergic agonist metoprolol (marketed as a combination product) to potentially mitigate cardiovascular concerns (Sjodin et al., 2020).

Tesofensine's pharmacology is distinct from currently approved anti-obesity drugs. While semaglutide and other GLP-1 receptor agonists work through incretin-based pathways, and phentermine acts primarily as a norepinephrine-dopamine releasing agent, tesofensine inhibits the reuptake of all three major monoamine neurotransmitters simultaneously. This triple action produces both appetite suppression (serotonin and norepinephrine mediated) and an increase in resting energy expenditure (norepinephrine and dopamine mediated) — a dual mechanism that may explain its exceptional efficacy in clinical trials (Hansen et al., 2010).

Quick Facts

Tesofensine vs. Approved Weight Loss Drugs: Efficacy Snapshot

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Tesofensine's pharmacology is anchored in its ability to simultaneously modulate three major monoamine neurotransmitter systems. Understanding how each system contributes to weight regulation clarifies why triple reuptake inhibition produces such potent anti-obesity effects.

Serotonin Reuptake Inhibition (SERT Blockade)

Serotonin (5-hydroxytryptamine, 5-HT) is a critical regulator of appetite and satiety. By blocking the serotonin transporter (SERT), tesofensine increases synaptic serotonin concentrations in the hypothalamus and brainstem feeding centers. Elevated serotonin acts on 5-HT2C and 5-HT1B receptors in the arcuate nucleus and paraventricular nucleus of the hypothalamus to promote satiety and reduce food intake (Hansen et al., 2010).

The serotonergic contribution to appetite suppression is well-established. Lorcaserin (Belviq), a selective 5-HT2C agonist, produced moderate weight loss (~5–7%) through this mechanism alone. Tesofensine's serotonergic effect provides the foundation of its appetite-suppressing activity, but it is the combination with norepinephrine and dopamine effects that amplifies the weight-loss response beyond what serotonin modulation alone can achieve (Astrup et al., 2008).

Norepinephrine Reuptake Inhibition (NET Blockade)

Norepinephrine (NE) plays a dual role in weight regulation: it suppresses appetite centrally and increases energy expenditure peripherally. By blocking the norepinephrine transporter (NET), tesofensine elevates synaptic NE concentrations in both the brain and the sympathetic nervous system.

• Central appetite suppression: Elevated NE in the lateral hypothalamus reduces food-seeking behavior and meal size through alpha-1 and beta-2 adrenergic receptor activation (Hansen et al., 2010).
• Peripheral energy expenditure: Increased sympathetic NE tone activates beta-adrenergic receptors in brown and beige adipose tissue, stimulating uncoupling protein 1 (UCP1) expression and thermogenesis. This increases resting metabolic rate, meaning the body burns more calories even at rest. Human studies with tesofensine confirmed a significant increase in resting energy expenditure — approximately 6% above baseline — contributing to the observed weight loss (Hansen et al., 2010).
• Cardiovascular effects: The same sympathomimetic mechanism that increases energy expenditure also increases heart rate and blood pressure, which is the primary safety concern with tesofensine.

Dopamine Reuptake Inhibition (DAT Blockade)

Dopamine modulation is perhaps the most pharmacologically distinctive aspect of tesofensine's mechanism. By blocking the dopamine transporter (DAT), tesofensine increases synaptic dopamine in the mesolimbic reward system, including the nucleus accumbens and ventral tegmental area. This has several implications for weight management:

• Reward system modulation: Elevated dopamine in the reward circuitry may reduce the hedonic drive to overeat by partially satisfying reward pathways that otherwise demand stimulation through highly palatable foods. This is conceptually similar to how bupropion (a weaker NET/DAT inhibitor) reduces food cravings in the naltrexone-bupropion (Contrave) combination (Heal et al., 2012).
• Mood and motivation: Dopamine elevation improves mood, motivation, and energy — effects that may improve adherence to dietary and exercise programs. Depression and anhedonia are common barriers to weight management, and dopaminergic augmentation may address these indirectly (Heal et al., 2012).
• Metabolic contribution: Dopamine has direct effects on hepatic glucose metabolism and insulin sensitivity, and may contribute to the metabolic improvements observed with tesofensine beyond weight loss alone (Axel et al., 2010).

The Dual Mechanism: Appetite Suppression + Energy Expenditure

Most anti-obesity drugs work through a single primary mechanism. GLP-1 agonists primarily reduce appetite. Orlistat reduces fat absorption. Phentermine primarily suppresses appetite through sympathomimetic effects. Tesofensine is notable because it produces weight loss through two distinct but complementary mechanisms:

1. Reduced caloric intake: Through serotonergic and noradrenergic satiety signaling, tesofensine reduces appetite, decreases food cravings, and increases feelings of fullness. In the Phase II TIPO-1 trial, caloric intake was reduced by approximately 26% in the 1.0 mg group compared to baseline (Astrup et al., 2008).
2. Increased energy expenditure: Through noradrenergic and dopaminergic sympathetic activation, tesofensine increases resting metabolic rate by approximately 6%. While this may seem modest, over 24 weeks it represents a substantial cumulative caloric deficit that adds to the deficit created by reduced food intake (Hansen et al., 2010).

This dual mechanism may explain why tesofensine produced greater weight loss at 24 weeks than drugs that work primarily through appetite suppression alone. Mathematical modeling of the Phase II data suggests that approximately 60–70% of the weight loss was attributable to reduced food intake and 30–40% to increased energy expenditure (Hansen et al., 2010).

Binding Affinity Profile

Tesofensine's selectivity across the three monoamine transporters is not equal. It has the highest affinity for the norepinephrine transporter (NET), moderate affinity for the serotonin transporter (SERT), and lower but clinically meaningful affinity for the dopamine transporter (DAT). This binding profile is considered favorable for weight loss because it maximizes appetite suppression and thermogenesis while keeping dopaminergic stimulation within a range that reduces abuse potential relative to more potent DAT inhibitors like cocaine or amphetamine (Heal et al., 2012).

Pharmacokinetics

A defining pharmacokinetic feature of tesofensine is its extremely long half-life. The parent compound has a half-life of approximately 220 hours (9 days), and its active metabolite M1 (desmethyl-tesofensine) has an even longer half-life of approximately 260 hours (11 days). This means:

• Once-daily dosing is sufficient and convenient.
• Steady-state concentrations are not reached until approximately 8 weeks of daily dosing. This means the full pharmacological effect of tesofensine develops gradually, and early-period weight loss may underestimate the drug's eventual efficacy.
• Washout after discontinuation is extremely slow. Drug effects persist for weeks after the last dose, which is an important consideration for managing side effects and drug interactions.
• Dose adjustments take weeks to produce meaningful changes in plasma levels, requiring patience and careful titration.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Tesofensine has no FDA-approved indication. It has completed Phase II clinical trials for obesity with promising results, and Phase III trials are underway outside the United States. The compound was originally investigated for Parkinson's disease and Alzheimer's disease, but clinical development for these indications was discontinued after Phase II when neurological efficacy was not demonstrated, although weight loss was consistently observed as a side effect (Hauser et al., 2007).

Clinical Development History

Obesity Treatment (Primary Current Indication)

The TIPO-1 Phase II trial established tesofensine as an investigational anti-obesity agent. Key inclusion criteria were adults with a body mass index (BMI) of 30–40 kg/m², aged 18–65 years. All subjects received dietary counseling and were instructed to follow a mildly hypocaloric diet (300 kcal/day deficit). Tesofensine at 0.25 mg, 0.5 mg, and 1.0 mg was compared to placebo over 24 weeks (Astrup et al., 2008).

The results suggested tesofensine's potential role in treating:

• Obesity with failed prior therapy: Patients who have not achieved adequate weight loss with diet, exercise, or existing medications may benefit from a more potent pharmacological agent.
• Obesity with metabolic syndrome: Tesofensine improved fasting insulin, insulin sensitivity (HOMA-IR), and lipid profiles beyond what could be explained by weight loss alone, suggesting direct metabolic benefits (Axel et al., 2010).
• Obesity with binge eating or reward-driven overeating: The dopaminergic component of tesofensine's mechanism may be particularly relevant for patients whose obesity is driven by hedonic overeating and food reward dysfunction.

Neurodegenerative Disease (Abandoned Indication)

The original development of tesofensine for Parkinson's disease was based on its ability to increase dopamine levels in the basal ganglia through DAT inhibition, which could theoretically supplement the declining dopaminergic function that characterizes Parkinson's. Similarly, its norepinephrine and serotonin effects were hypothesized to improve cognitive function in Alzheimer's disease (Hauser et al., 2007).

Phase II trials for both conditions showed that tesofensine was well-tolerated and produced significant weight loss in patients, but did not demonstrate meaningful improvement in the primary neurological endpoints. The Parkinson's trial (PEMTD) showed no significant improvement in UPDRS (Unified Parkinson's Disease Rating Scale) motor scores compared to placebo. These failures for neurological indications, combined with the striking weight-loss observations, prompted the strategic pivot to obesity (Hauser et al., 2007).

What Tesofensine Is NOT Used For

• Approved weight-loss therapy: Despite promising Phase II data, tesofensine is not approved anywhere for obesity treatment. It remains investigational.
• Depression: While tesofensine's triple reuptake inhibition profile resembles some antidepressants, it has not been developed or tested as an antidepressant. Its binding profile is not optimized for depression treatment, and it has not undergone clinical trials for mood disorders.
• ADHD: Although DAT and NET inhibition are relevant to ADHD pharmacology, tesofensine has not been studied for attention deficit disorders.
• Athletic performance enhancement: Tesofensine is not a performance-enhancing drug. While its sympathomimetic effects could theoretically enhance endurance, it is not used or studied for this purpose.
• Short-term or cosmetic weight loss: Given its extremely long half-life and cardiovascular risks, tesofensine is not appropriate for minor or cosmetic weight loss goals.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Doses Used in Published Clinical Trials

Key dosing references: Astrup et al., 2008 · Hauser et al., 2007

Dose-Response Relationship (Phase II Data)

The dose-response was clear and linear across the three doses tested. However, the cardiovascular effects also increased dose-dependently. The 0.5 mg dose was identified by investigators as the likely optimal dose for further development, balancing meaningful weight loss (~9.2%) with more manageable cardiovascular signals compared to 1.0 mg (Astrup et al., 2008).

Steady-State Considerations

Due to tesofensine's exceptionally long half-life (~9 days for the parent compound), several important dosing principles apply:

• Gradual onset: Plasma concentrations accumulate slowly. Full pharmacological effects (including peak appetite suppression and energy expenditure increase) are not reached until approximately 8 weeks of daily dosing. Patients and clinicians should not judge efficacy based on the first 4–6 weeks.
• No dose titration schedule in published trials: In the TIPO-1 trial, patients were started directly on their assigned dose without a titration period. However, some practitioners prescribing tesofensine off-label have used a graduated approach (starting at 0.25 mg for 2–4 weeks before increasing) to assess tolerability, particularly regarding cardiovascular effects (Astrup et al., 2008).
• Slow washout: After discontinuation, drug effects persist for 4–6 weeks due to the long half-life. This is important for managing transitions to other medications, scheduling surgical procedures, or addressing side effects.
• Missed doses: Because of the long half-life and the substantial drug reservoir at steady state, missing a single daily dose has minimal impact on plasma levels. This is pharmacokinetically advantageous for adherence.

Administration

• Timing: Tesofensine can be taken at any time of day, with or without food. In clinical trials, it was administered in the morning. Given its stimulant-like properties (norepinephrine and dopamine elevation), morning dosing is generally preferred to minimize potential sleep disruption.
• Food interaction: No significant food-drug interactions have been reported. Tesofensine can be taken with or without meals.
• CYP3A4 interactions: Tesofensine is metabolized by CYP3A4/5 enzymes. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) may increase tesofensine levels. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may decrease levels. These interactions should be carefully evaluated.

Monitoring During Treatment

Based on the safety signals observed in clinical trials, the following monitoring is recommended for patients receiving tesofensine under clinical supervision:

• Heart rate and blood pressure: Baseline, then at weeks 2, 4, 8, 12, and monthly thereafter. The most clinically relevant cardiovascular changes occur during the first 8 weeks as drug accumulates to steady state.
• Resting heart rate >100 bpm (tachycardia) or systolic BP >140 mmHg should prompt dose reduction or discontinuation.
• Psychiatric assessment: Monitor for anxiety, insomnia, agitation, mood changes, and suicidal ideation (the latter due to the serotonergic mechanism, per standard precautions for serotonin-modulating drugs).
• Metabolic labs: Fasting glucose, HbA1c, lipid panel, liver function tests at baseline and periodically.
• Weight: Regular weigh-ins to track efficacy and identify any unexpected changes.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Clinical Trials Show

TIPO-1 Trial: Primary Outcomes

The TIPO-1 trial (Tesofensine In the treatment of Patients with Obesity) was a 24-week, randomized, double-blind, placebo-controlled trial conducted at sites across Denmark, Austria, and Australia. It enrolled 203 obese adults (BMI 30–40 kg/m²) who were randomized to placebo, tesofensine 0.25 mg, 0.5 mg, or 1.0 mg once daily. All groups received dietary counseling targeting a 300 kcal/day deficit (Astrup et al., 2008).

Metabolic Improvements

Beyond weight loss, tesofensine produced significant improvements in metabolic parameters that are risk factors for cardiovascular disease and type 2 diabetes:

These metabolic improvements are consistent with, but may exceed, what would be expected from the degree of weight loss alone. The investigators suggested that tesofensine's direct effects on norepinephrine and dopamine signaling may contribute to insulin sensitization and lipid improvement independent of weight reduction (Axel et al., 2010).

Body Composition

DEXA (dual-energy X-ray absorptiometry) scans performed during the trial showed that approximately 75–80% of the weight lost was fat mass and 20–25% was lean mass. This ratio is generally consistent with what is observed with caloric restriction and pharmacotherapy in obese subjects. The lean mass loss at the 1.0 mg dose (~3.1 kg) was somewhat higher in absolute terms due to the greater total weight loss, but the percentage of lean mass loss was similar across dose groups (Astrup et al., 2008).

Energy Expenditure and Food Intake

Indirect calorimetry studies conducted during the trial confirmed tesofensine's dual mechanism:

• Resting energy expenditure (REE): Increased by approximately 6% in the 0.5 mg group and 8% in the 1.0 mg group, compared to no significant change in placebo. This is notable because weight loss typically decreases REE (metabolic adaptation), meaning tesofensine was counteracting this metabolic slowdown (Hansen et al., 2010).
• Self-reported food intake: Decreased by approximately 18% in the 0.5 mg group and 26% in the 1.0 mg group. Patients reported significantly reduced appetite and cravings, particularly for high-calorie, high-fat foods (Astrup et al., 2008).
• Fat oxidation: Increased significantly in the tesofensine groups, consistent with sympathetically-mediated lipolysis.

Cardiovascular Outcomes (Phase II Safety Signals)

The cardiovascular effects were dose-dependent and statistically significant at 0.5 mg and 1.0 mg. While the absolute increases appear modest (5–7 bpm heart rate, 2–3 mmHg blood pressure), regulatory agencies view these signals seriously in the context of a drug intended for chronic use in obese patients who already have elevated cardiovascular risk. The withdrawal of sibutramine (Meridia) in 2010 — which had a similar but more pronounced cardiovascular profile — established a precedent that influenced the cautious regulatory approach to tesofensine (Astrup et al., 2008).

Timeline of Weight Loss

Weight loss was continuous throughout the 24-week treatment period, with no plateau observed by week 24. This suggests that longer treatment durations might produce additional weight loss, although this has not been tested beyond 24 weeks in published Phase II data. The trajectory also aligns with the long time to reach steady-state plasma concentrations (~8 weeks), with acceleration of weight loss observed between weeks 6–12 as drug levels reached their full effect (Astrup et al., 2008).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Side Effects Reported in Clinical Studies

Cardiovascular Safety: The Central Concern

The cardiovascular effects of tesofensine are the most important safety consideration and the primary reason the compound has not received FDA approval to date. The concerns are rooted in both the clinical data and regulatory precedent:

• Sibutramine precedent: Sibutramine (Meridia/Reductil), a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for obesity in 1997, was withdrawn from the market in 2010 after the SCOUT trial showed increased cardiovascular events (non-fatal heart attacks and strokes) in patients with pre-existing cardiovascular disease. Sibutramine increased heart rate by 3–5 bpm and blood pressure by 1–3 mmHg — a profile similar to tesofensine. This withdrawal created a strong regulatory precedent against approving anti-obesity drugs with sympathomimetic cardiovascular effects (James et al., 2010).
• Tesofensine's additional DAT component: Unlike sibutramine, tesofensine also blocks the dopamine transporter. While this may contribute to greater weight loss, it adds another dimension of cardiovascular and psychiatric risk. Dopaminergic stimulation can increase heart rate and blood pressure independently of noradrenergic effects.
• Target population risk: Obese patients often have hypertension, pre-diabetes, dyslipidemia, and other cardiovascular risk factors. Even modest increases in heart rate and blood pressure in this population could translate to increased cardiovascular event rates over long-term use.
• FDA cardiovascular outcome trial requirement: Since 2012, the FDA has generally required anti-obesity drugs to demonstrate cardiovascular safety, either pre-approval or as a post-marketing commitment. This would require a large, long-term cardiovascular outcomes trial (CVOT) for tesofensine — a study that would cost hundreds of millions of dollars and take years to complete.

Psychiatric Safety Considerations

As a triple monoamine reuptake inhibitor, tesofensine modulates the same neurotransmitter systems targeted by antidepressants (SSRIs, SNRIs) and psychostimulants (amphetamines, methylphenidate). This raises several psychiatric safety considerations:

• Suicidality: Serotonin-modulating drugs carry an FDA black box warning for increased suicidal thinking in adolescents and young adults. While no suicidal events were reported in tesofensine's clinical trials, the trials were not powered to detect rare psychiatric events, and the serotonergic mechanism warrants vigilant monitoring (Heal et al., 2012).
• Serotonin syndrome: Combining tesofensine with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, MAO inhibitors) could theoretically precipitate serotonin syndrome. This combination should be avoided or used with extreme caution.
• Abuse potential: DAT inhibition is the mechanism shared by drugs of abuse like cocaine and amphetamine. However, tesofensine's DAT binding affinity is substantially lower than these substances, and its extremely long half-life makes it poorly suited for the rapid onset/offset kinetics that drive abuse. Preclinical abuse-liability studies suggest low but non-zero abuse potential (Heal et al., 2012).
• Insomnia and anxiety: These were the most commonly reported psychiatric effects in clinical trials. They are expected consequences of noradrenergic and dopaminergic stimulation and are generally manageable with dose adjustment and behavioral measures.

Comparison of Side Effects: Tesofensine vs. Sibutramine

Contraindications (Based on Mechanism and Clinical Data)

• Uncontrolled hypertension — tesofensine raises blood pressure
• Tachyarrhythmias or resting heart rate >100 bpm — tesofensine increases heart rate
• Recent cardiovascular event (MI, stroke within 6 months)
• Concurrent MAO inhibitor use — risk of hypertensive crisis and serotonin syndrome
• Concurrent use of other serotonergic drugs without careful supervision
• History of seizures — monoamine reuptake inhibitors may lower seizure threshold
• Narrow-angle glaucoma — sympathomimetic effects may increase intraocular pressure
• Pregnancy and breastfeeding — no safety data
• Active substance abuse — given dopaminergic mechanism
• Severe hepatic impairment — CYP3A4 metabolism could be impaired

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Comparisons: Tesofensine vs. Other Weight Loss Therapies

Tesofensine vs. GLP-1 Receptor Agonists (Semaglutide, Liraglutide)

The most important distinction is that GLP-1 agonists have demonstrated cardiovascular benefit (reduced MACE events in the SELECT trial for semaglutide) while tesofensine shows cardiovascular risk signals. Additionally, semaglutide's Phase III data at 68 weeks likely exceeds what tesofensine would achieve at 24 weeks even if the curve continued, though direct comparison is complicated by different trial durations, populations, and designs (Wilding et al., 2021).

A potential advantage of tesofensine is its effect on energy expenditure. GLP-1 agonists do not increase resting metabolic rate and may even decrease it as weight is lost (metabolic adaptation). Tesofensine's ability to maintain or increase energy expenditure during weight loss could theoretically result in better long-term weight maintenance, though this has not been demonstrated in trials.

Tesofensine vs. Tirzepatide (Zepbound/Mounjaro)

Tirzepatide produces substantially greater weight loss than tesofensine and does so with a more favorable cardiovascular profile. In practical terms, tirzepatide's emergence as the most effective available anti-obesity drug has further complicated the commercial case for tesofensine in Western markets (Jastreboff et al., 2022).

Tesofensine vs. Phentermine

Phentermine is the most widely prescribed weight-loss drug in the United States due to its low cost and decades of clinical familiarity. Tesofensine produces greater weight loss but has a similar cardiovascular risk profile and lacks approval. Phentermine's much shorter half-life allows for flexible dosing (e.g., drug holidays) and faster washout if side effects develop. Tesofensine's 9-day half-life means cardiovascular side effects, once established, persist for weeks after discontinuation (Heal et al., 2012).

Tesofensine vs. Naltrexone-Bupropion (Contrave)

Naltrexone-bupropion shares some mechanistic overlap with tesofensine (both affect norepinephrine and dopamine), but tesofensine adds serotonergic activity and produces approximately twice the weight loss. However, Contrave has a more manageable cardiovascular profile and is FDA-approved. The bupropion component of Contrave is a weaker NET/DAT inhibitor than tesofensine, and the naltrexone component adds opioid-receptor-mediated appetite suppression that tesofensine lacks (Heal et al., 2012).

Unique Advantages and Disadvantages of Tesofensine

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Key Published Clinical Trials

TIPO-1: Phase II Obesity Trial (Astrup et al., 2008)

This is the pivotal study underpinning tesofensine's reputation as a potent anti-obesity agent. Published in The Lancet, TIPO-1 randomized 203 obese adults (BMI 30–40) to tesofensine 0.25 mg, 0.5 mg, 1.0 mg, or placebo for 24 weeks, with all groups receiving dietary counseling. Key findings:

• Dose-dependent weight loss: 4.5%, 9.2%, and 12.8% at the three doses vs. 2.0% for placebo (all p<0.001 vs. placebo).
• The 1.0 mg dose produced greater weight loss than any other anti-obesity agent tested in a placebo-controlled trial at the time.
• Weight loss was continuous throughout 24 weeks with no plateau, suggesting additional loss with longer treatment.
• Dose-dependent cardiovascular signals: heart rate increased +3.1 to +7.4 bpm; systolic BP increased +1.5 to +3.4 mmHg.
• Dropout rates were 10–15% across groups, comparable to placebo and suggesting acceptable tolerability.
• The study identified 0.5 mg as the dose with the best benefit-risk ratio for further development (Astrup et al., 2008).

PEMTD: Phase II Parkinson's Disease Trial (Hauser et al., 2007)

This multicenter trial enrolled 261 patients with early Parkinson's disease and randomized them to tesofensine 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, or placebo for 14 weeks. Results:

• No significant improvement in UPDRS motor scores at any dose (the primary endpoint was negative).
• Significant weight loss was observed as a side effect across all dose groups, prompting the pivot to obesity development.
• Tesofensine was well-tolerated, with side effects consistent with its pharmacological profile (dry mouth, insomnia, nausea).
• The trial provided important safety and pharmacokinetic data that informed subsequent obesity trial design (Hauser et al., 2007).

Alzheimer's Disease Phase II (NeuroSearch, 2004–2005)

A Phase II trial in patients with mild-to-moderate Alzheimer's disease evaluated tesofensine at 0.25 mg and 0.5 mg for 14 weeks. The trial failed to show significant cognitive improvement on primary endpoints. Weight loss was again observed. This trial was not published in full in a peer-reviewed journal but results were disclosed by NeuroSearch in regulatory filings (Heal et al., 2012).

Preclinical Research

Energy Expenditure and Thermogenesis

Animal studies using diet-induced obese (DIO) rats demonstrated that tesofensine produced significantly greater weight loss than pair-fed controls (animals given the same reduced food intake). This confirmed that tesofensine's weight-loss effect is not solely due to appetite suppression but also involves increased energy expenditure. The thermogenic effect was associated with increased brown adipose tissue (BAT) activation and elevated UCP1 expression, consistent with sympathetically-mediated thermogenesis (Hansen et al., 2010).

Metabolic Effects

Preclinical and clinical studies have examined tesofensine's metabolic effects independent of weight loss:

• Insulin sensitivity: Tesofensine improved insulin sensitivity (HOMA-IR) by 30–39% in the TIPO-1 trial, exceeding what would be expected from the magnitude of weight loss alone. This suggests direct effects on insulin signaling, possibly through dopaminergic modulation of hepatic glucose production (Axel et al., 2010).
• Lipid metabolism: Triglycerides and LDL cholesterol decreased significantly, while HDL cholesterol increased. Fat oxidation was enhanced, consistent with noradrenergic stimulation of lipolysis.
• Adipokines: Limited data suggest tesofensine may affect leptin and adiponectin levels, though this has not been comprehensively characterized in humans.

Gut Microbiome

Emerging research has explored whether tesofensine's serotonergic effects influence the gut-brain axis and gut microbiome composition. Approximately 95% of the body's serotonin is produced in the gut, and drugs that modulate serotonin signaling can alter gut motility, microbiome composition, and enteroendocrine function. Preliminary animal data suggest tesofensine may shift microbiome composition toward a profile associated with leanness, though this research is early-stage and has not been confirmed in humans (Sjodin et al., 2020).

Combination Approaches

Recognizing that tesofensine's cardiovascular effects are its primary liability, researchers have investigated combination strategies to mitigate heart rate and blood pressure increases while preserving weight-loss efficacy:

• Tesofensine + metoprolol: Medix is developing a fixed-dose combination of tesofensine with the beta-1 selective blocker metoprolol. The rationale is that metoprolol can counteract the noradrenergically-mediated heart rate increase while preserving or enhancing the weight-loss effect. Preclinical data suggested this combination maintained weight-loss efficacy while normalizing heart rate. Phase III trials with this combination are underway in Mexico (Sjodin et al., 2020).
• Lower-dose strategies: Tesofensine at 0.25 mg produced modest weight loss (4.5%) with minimal cardiovascular effects. Combining 0.25 mg tesofensine with complementary agents (e.g., GLP-1 agonists, metformin) could theoretically provide additive weight loss while keeping cardiovascular effects below clinically concerning thresholds, though this has not been tested.

Ongoing and Planned Clinical Trials

Prader-Willi Syndrome (Orphan Indication)

Saniona has explored tesofensine (as the combination product Tesomet with metoprolol) for Prader-Willi syndrome (PWS), a rare genetic condition characterized by insatiable appetite and severe obesity. PWS patients have dysfunctional hypothalamic appetite signaling, and the triple monoamine reuptake inhibition of tesofensine may address aspects of this dysfunction. Preliminary Phase II data showed reduced hyperphagia scores and weight stabilization, prompting further investigation. PWS offers a potential orphan drug pathway with lower regulatory barriers than general obesity (Sjodin et al., 2020).

Research Limitations

• Single pivotal Phase II trial: The TIPO-1 trial, while well-designed and published in The Lancet, is a single study. Phase III replication is needed to confirm efficacy and refine the safety profile.
• 24-week duration limit: No published data extends beyond 24 weeks. Long-term efficacy, weight maintenance, and safety remain unknown.
• No cardiovascular outcomes trial: Given the heart rate and blood pressure signals, a large CVOT would be needed for Western regulatory approval. This study does not yet exist.
• Limited diversity: The TIPO-1 trial was conducted primarily in European and Australian populations. Efficacy and safety in more diverse populations need confirmation.
• Combination data is limited: The tesofensine + metoprolol combination concept is promising but full Phase III data has not been published.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Tesofensine has no FDA-approved indication. It has not been submitted for FDA review, and no IND (Investigational New Drug) application for U.S. clinical trials is currently publicly disclosed. The FDA's stringent requirements for cardiovascular outcome data in anti-obesity drugs, combined with the sibutramine precedent, represent a substantial barrier to U.S. approval without a clean cardiovascular outcomes trial.

Development Timeline

Regulatory Challenges

Several factors have complicated tesofensine's path to market approval:

• Post-sibutramine regulatory climate: The 2010 withdrawal of sibutramine created a lasting regulatory precedent. The FDA has since required or strongly encouraged cardiovascular outcome trials (CVOTs) for anti-obesity drugs, particularly those with sympathomimetic mechanisms. This requirement adds years and hundreds of millions of dollars to the development program.
• Cardiovascular signals: The dose-dependent increases in heart rate and blood pressure observed in TIPO-1, while modest in absolute terms, are viewed as unacceptable risk signals by Western regulators in the absence of a clean CVOT.
• Financial instability of original developer: NeuroSearch's financial collapse disrupted the development program at a critical juncture (between Phase II and Phase III).
• Competitive landscape evolution: The approval of highly effective GLP-1 agonists (semaglutide in 2021, tirzepatide in 2023) has raised the bar for new anti-obesity drug approval. Regulators and payers now expect significant weight loss plus cardiovascular safety or benefit — a combination tesofensine has not demonstrated.

Current Development Programs

Medix (Mexico)

Medix, a Mexican pharmaceutical company focused on obesity and metabolic disease, holds development and commercialization rights for tesofensine in Mexico and potentially other Latin American markets. Medix has advanced tesofensine into Phase III clinical trials and is developing it as a fixed-dose combination with metoprolol to address cardiovascular concerns. Mexico's regulatory agency (COFEPRIS) has a different approval framework than the FDA, and tesofensine may reach the Mexican market before any Western regulatory approval.

Saniona (Denmark)

Saniona, the successor company to NeuroSearch, retains rights to tesofensine outside of Mexico. Saniona's strategy focuses on the Tesomet combination (tesofensine + metoprolol) for rare disease indications:

• Prader-Willi syndrome: An orphan indication with high unmet medical need and potentially faster regulatory review (orphan drug designation provides incentives including market exclusivity and reduced regulatory requirements).
• Hypothalamic obesity: Obesity caused by hypothalamic damage (e.g., from craniopharyngioma treatment), another orphan-qualifying condition with few treatment options.

International Regulatory Overview

Controlled Substance Status

Tesofensine is not currently classified as a controlled substance in the United States, European Union, or most other jurisdictions. Despite its dopamine transporter inhibition, preclinical abuse-liability assessments suggest low abuse potential due to its long half-life (rapid onset is a key driver of abuse potential, and tesofensine's pharmacokinetics produce a very gradual onset). However, if tesofensine were to receive regulatory approval, its scheduling status would be evaluated by the DEA based on abuse-liability data (Heal et al., 2012).

Access Today

As of early 2026, legitimate access to tesofensine is limited:

• Clinical trials: Enrollment in active Medix or Saniona clinical trials is the primary legitimate access route.
• Mexico: Some clinics and practitioners in Mexico have reported prescribing tesofensine off-label or under compassionate-use frameworks, though the regulatory clarity of this practice is uncertain.
• Compounding pharmacies: Some U.S. compounding pharmacies have offered tesofensine as a compounded preparation. The legality and safety of this practice depend on the FDA's bulk drug substance evaluation, which is evolving.
• Research chemical market: Tesofensine is available through research chemical suppliers, with the standard caveats about quality, purity, and legal status.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Is tesofensine more effective than semaglutide (Wegovy) for weight loss?

Answer: It depends on the comparison. In the Phase II TIPO-1 trial, tesofensine at 1.0 mg produced 12.8% weight loss in 24 weeks. In the Phase III STEP 1 trial, semaglutide 2.4 mg produced 14.9% weight loss in 68 weeks. On a per-week basis, tesofensine's rate of weight loss was actually faster. However, these comparisons are imperfect: TIPO-1 was Phase II with 203 patients, while STEP 1 was Phase III with 1,961 patients. Trial designs, populations, and endpoints differed. More importantly, semaglutide has demonstrated cardiovascular benefit (reduced MACE events) while tesofensine has cardiovascular risk signals. The comparison is further complicated by tesofensine's 24-week treatment duration — we do not know what tesofensine would achieve at 68 weeks. In practical terms, semaglutide is FDA-approved and available; tesofensine is not (Astrup et al., 2008; Wilding et al., 2021).

Q: Is tesofensine just another amphetamine?

Answer: No. While tesofensine and amphetamines both affect monoamine neurotransmission, their mechanisms are fundamentally different. Amphetamines are releasing agents — they force monoamine transporters to run in reverse, dumping neurotransmitters into the synapse. This produces a rapid, intense surge of dopamine, norepinephrine, and serotonin. Tesofensine is a reuptake inhibitor — it blocks the transporter from vacuuming neurotransmitters out of the synapse, allowing naturally released monoamines to persist longer. This produces a gentler, more sustained elevation. Furthermore, tesofensine's extremely long half-life (~9 days) makes it pharmacokinetically unsuitable for the rapid onset-offset pattern that drives amphetamine abuse. Preclinical abuse-liability studies indicate low abuse potential for tesofensine (Heal et al., 2012).

Q: Why was tesofensine not approved if it works so well?

Answer: Three main reasons: (1) Cardiovascular safety signals — dose-dependent increases in heart rate and blood pressure raised concerns, especially after sibutramine was withdrawn in 2010 for causing cardiovascular events in a similar patient population; (2) Financial collapse of the original developer — NeuroSearch went bankrupt before Phase III could begin; and (3) Regulatory requirements — the FDA now generally requires cardiovascular outcome trials for anti-obesity drugs with sympathomimetic effects, which are extremely expensive and time-consuming. The compound's efficacy was never questioned; the barriers are safety, financial, and regulatory (James et al., 2010).

Q: Is tesofensine similar to sibutramine (Meridia)?

Answer: There are similarities and important differences. Both are monoamine reuptake inhibitors used for weight loss. Sibutramine blocked serotonin and norepinephrine reuptake (dual SNRI). Tesofensine adds dopamine reuptake inhibition (triple reuptake). Tesofensine produces greater weight loss (~9–13% vs. ~5–8% for sibutramine) but has a similar cardiovascular side-effect profile (increased HR and BP). Sibutramine's withdrawal after the SCOUT trial showed a 16% increase in cardiovascular events is the single most important cautionary tale for tesofensine. Whether tesofensine's cardiovascular risk is the same, worse, or better than sibutramine's cannot be determined without a dedicated cardiovascular outcomes trial (James et al., 2010).

Q: Can I get tesofensine prescribed in the United States?

Answer: Tesofensine is not FDA-approved, and there is no standard prescription pathway in the United States. Some compounding pharmacies have reported offering tesofensine preparations, but this exists in a regulatory gray area. The compound is available through research chemical suppliers, but these products are labeled "not for human consumption" and are not subject to pharmaceutical quality standards. The safest and most legitimate access is through enrollment in active clinical trials. Anyone claiming to offer FDA-approved or medically sanctioned tesofensine in the U.S. is misrepresenting the compound's regulatory status.

Q: How does tesofensine compare to phentermine for weight loss?

Answer: Tesofensine produces approximately twice the weight loss of phentermine in clinical trials (9–13% vs. 5–8%). Both drugs have sympathomimetic mechanisms and increase heart rate and blood pressure. Key differences: (1) Tesofensine has a ~9-day half-life vs. phentermine's ~20-hour half-life, meaning tesofensine effects persist for weeks after discontinuation while phentermine clears in days; (2) Tesofensine adds serotonergic activity, which phentermine lacks; (3) Phentermine is FDA-approved (since 1959), widely available, and costs $15–50/month; tesofensine is not approved and not readily available; (4) Phentermine is Schedule IV (some abuse potential); tesofensine is not currently scheduled (Heal et al., 2012).

Q: Does tesofensine increase energy or is it a stimulant?

Answer: Tesofensine increases norepinephrine and dopamine levels, which can produce subjective increases in energy, alertness, and motivation. In clinical trials, patients did not report significant stimulant-like subjective effects (euphoria, "wired" feeling), but insomnia was common (20–30%), suggesting meaningful sympathomimetic activation. The compound also objectively increases resting energy expenditure by approximately 6–8%, meaning the body burns more calories even at rest. Whether this qualifies as "stimulant" depends on the definition. Tesofensine is pharmacologically milder than classic stimulants (amphetamines, methylphenidate) but more activating than non-sympathomimetic anti-obesity drugs like orlistat or GLP-1 agonists (Hansen et al., 2010).

Q: What happens when you stop taking tesofensine? Do you regain the weight?

Answer: Published data on weight regain after tesofensine discontinuation is limited. The TIPO-1 trial did not include a formal post-treatment follow-up period. Based on the pharmacology of other anti-obesity drugs, weight regain after discontinuation is expected to some degree, as the mechanisms driving reduced appetite and increased energy expenditure would fade once drug levels decline. However, tesofensine's exceptionally long half-life means drug effects would taper very gradually over 4–6 weeks after the last dose, potentially providing a "soft landing" rather than an abrupt return of appetite. The general principle of obesity pharmacology applies: sustained treatment is needed for sustained benefit, and lifestyle modifications should be maintained regardless of drug use (Astrup et al., 2008).

Q: Can tesofensine be combined with a GLP-1 agonist?

Answer: This combination has not been studied in clinical trials, and no published data exists on the safety or efficacy of combining tesofensine with semaglutide, liraglutide, or tirzepatide. Theoretically, the mechanisms are complementary: GLP-1 agonists work through incretin signaling while tesofensine works through monoaminergic signaling. The combination could potentially produce additive weight loss. However, both drug classes can increase heart rate, and the combination's cardiovascular safety would need careful evaluation. Additionally, severe nausea could result from combining GLP-1-mediated GI effects with serotonergic nausea from tesofensine. Until clinical data is available, this combination should be considered speculative and potentially risky.

Q: Is tesofensine addictive?

Answer: Probably not significantly. While tesofensine inhibits the dopamine transporter (the mechanism associated with addiction in drugs like cocaine), several factors reduce its abuse potential: (1) its affinity for DAT is relatively low compared to drugs of abuse; (2) its extremely long half-life (~9 days) produces a very gradual onset of dopaminergic effects, unlike the rapid onset that drives abuse; (3) preclinical self-administration studies in animals showed low abuse liability; and (4) no addictive behavior was observed in any clinical trial. However, individuals with a history of substance abuse should exercise caution, and long-term abuse potential has not been comprehensively evaluated in large populations (Heal et al., 2012).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence from published clinical trials, preclinical research, and established pharmacology:

• Tesofensine is one of the most potent oral weight-loss compounds ever tested in clinical trials. The 1.0 mg dose produced 12.8% body weight loss over 24 weeks in the Phase II TIPO-1 trial — approximately double the efficacy of most approved oral anti-obesity drugs. Even the 0.5 mg dose produced 9.2% weight loss, rivaling the efficacy of the phentermine-topiramate combination (Qsymia).
• It works through a unique dual mechanism. Unlike most anti-obesity drugs that primarily reduce appetite, tesofensine both suppresses appetite (via serotonin and norepinephrine) and increases resting energy expenditure (via norepinephrine and dopamine). This "eat less and burn more" mechanism may explain its exceptional efficacy and may counteract the metabolic adaptation (decreased metabolic rate) that typically accompanies weight loss.
• Cardiovascular safety is the primary concern. Dose-dependent increases in heart rate (+3 to +7 bpm) and blood pressure (+1.5 to +3.4 mmHg systolic) were observed in Phase II. These signals are similar to those that led to sibutramine's withdrawal from the market in 2010. No cardiovascular outcomes trial has been completed for tesofensine.
• It is NOT FDA-approved. Despite a decade of development, tesofensine remains investigational. The combination of cardiovascular safety concerns, regulatory requirements for CVOTs, and the original developer's bankruptcy has prevented approval in any Western jurisdiction.
• Development continues in Mexico and Denmark. Medix is conducting Phase III trials in Mexico with a tesofensine-metoprolol combination designed to mitigate cardiovascular effects. Saniona is pursuing orphan drug pathways (Prader-Willi syndrome, hypothalamic obesity) in Europe.
• It was discovered by accident. Tesofensine was originally developed for Parkinson's and Alzheimer's disease. Its weight-loss effect was an unexpected side effect observed during neurological trials, prompting a strategic pivot to obesity.
• The extremely long half-life (~9 days) is both an advantage and a disadvantage. It allows convenient once-daily dosing and reduces the impact of missed doses. However, it also means side effects persist for weeks after discontinuation, and drug interactions require careful long-term management.
• Metabolic benefits extend beyond weight loss. Tesofensine significantly improved insulin sensitivity, triglycerides, and cholesterol in clinical trials, suggesting metabolic benefits that may exceed what would be expected from weight loss alone.
• The competitive landscape has shifted dramatically. When tesofensine's Phase II data was published in 2008, it was potentially the most effective weight-loss drug ever tested. Since then, semaglutide (~15% loss) and tirzepatide (~21% loss) have raised the efficacy bar substantially, and both have favorable cardiovascular profiles.
• Product quality concerns exist. Tesofensine is available through research chemical suppliers and some compounding pharmacies, but it is not subject to pharmaceutical manufacturing standards in these channels. Quality, purity, and dosing accuracy cannot be guaranteed outside of clinical trials or regulated pharmaceutical production.

Who Might Benefit from Tesofensine (If and When Approved)

Based on the pharmacological profile and clinical data, tesofensine may eventually be most appropriate for:

• Obese adults who have not responded adequately to GLP-1 agonists or other available therapies
• Patients who prefer oral medication over injectable therapy
• Patients whose obesity is driven by reward-based overeating (hedonic hyperphagia), where the dopaminergic component may be particularly beneficial
• Patients with Prader-Willi syndrome or hypothalamic obesity (orphan indications being pursued)
• Patients who experience significant metabolic adaptation (decreased metabolic rate) during weight loss with other therapies, where tesofensine's energy-expenditure-boosting effect may be advantageous

Who Should NOT Use Tesofensine

• Individuals with uncontrolled hypertension or tachycardia
• Anyone with recent cardiovascular events (heart attack, stroke)
• Individuals currently taking MAO inhibitors or multiple serotonergic drugs
• People with a history of seizures
• Individuals with active psychiatric disorders (severe anxiety, psychosis, suicidal ideation)
• Pregnant or breastfeeding women
• Individuals with substance abuse history (given dopaminergic mechanism)
• Anyone without access to medical supervision and cardiovascular monitoring

Questions to Ask a Provider

• Given my cardiovascular health and blood pressure, is a sympathomimetic weight-loss agent appropriate for me?
• How does tesofensine compare to FDA-approved options for my specific situation?
• What monitoring protocol (heart rate, blood pressure, psychiatric assessment) will be followed?
• Where is the tesofensine being sourced, and what quality testing has been performed?
• What interactions with my current medications need to be considered, especially any serotonergic drugs?
• What is the plan for discontinuation, and how will the long half-life affect the transition?
• Am I eligible for any active clinical trials that would provide monitored access?
• Have you considered the tesofensine + metoprolol combination to manage cardiovascular effects?

Sources & Further Reading

Pivotal Clinical Trials

• Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. (2008) — "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." The Lancet, 372(9653):1906-1913. The landmark TIPO-1 Phase II obesity trial demonstrating 12.8% weight loss at 1.0 mg over 24 weeks.
• Hauser RA, Salin L, Juhel N, Konyago VL. (2007) — "Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease." Movement Disorders, 22(3):359-365. Phase II Parkinson's disease trial where weight loss was discovered as a side effect.

Pharmacology & Mechanism of Action

• Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. (2010) — "The effect of tesofensine on energy expenditure, appetite, and food intake in obese subjects." International Journal of Obesity, 34(11):1634-1643. Detailed mechanistic study demonstrating dual appetite suppression and energy expenditure increase.
• Heal DJ, Gosden J, Smith SL. (2012) — "What is the prognosis for new centrally-acting anti-obesity drugs?" Neuropharmacology, 63(1):132-146. Comprehensive review of triple reuptake inhibitors including tesofensine's pharmacology, abuse potential, and regulatory prospects.
• Axel AM, Mikkelsen JD, Hansen HH. (2010) — "Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat." Neuropsychopharmacology, 35(7):1464-1476. Preclinical pharmacological characterization of appetite and metabolic mechanisms.

Cardiovascular Safety & Sibutramine Precedent

• James WPT, Caterson ID, Coutinho W, et al. (2010) — "Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects." The New England Journal of Medicine, 363(10):905-917. The SCOUT trial that led to sibutramine withdrawal and established the regulatory precedent affecting tesofensine.

Comparator Drug Trials (For Context)

• Wilding JPH, Batterham RL, Calanna S, et al. (2021) — "Once-weekly semaglutide in adults with overweight or obesity." The New England Journal of Medicine, 384(11):989-1002. The STEP 1 trial establishing semaglutide 2.4 mg efficacy for weight loss (~14.9% at 68 weeks).
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022) — "Tirzepatide once weekly for the treatment of obesity." The New England Journal of Medicine, 387(3):205-216. The SURMOUNT-1 trial establishing tirzepatide efficacy (~20.9% weight loss at 72 weeks).

Ongoing Development & Combination Approaches

• Sjodin A, Gasteyger C, Nielsen AL, et al. (2020) — "The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men." International Journal of Obesity, 34(11):1634-1643. Updated development strategy including combination approaches and Tesomet.

Reviews & Background

• Ioannides-Demos LL, Piccenna L, McNeil JJ. (2011) — "Pharmacotherapies for obesity: past, current, and future therapies." Journal of Obesity, 2011:179674. Review article placing tesofensine in context with other anti-obesity drugs.
• Billes SK, Sinnayah P, Bhatt DK, Bhatt SR, Cowley MA. (2012) — "Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss." Pharmacological Research, 84:1-11. Background on monoamine-based anti-obesity pharmacology.
• Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. (2008) — "Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease." Obesity, 16(6):1363-1369. Analysis of the weight-loss signal from the neurodegenerative disease trials that prompted the obesity development pivot.
• Adan RA, Vanderschuren LJ, la Fleur SE. (2008) — "Anti-obesity drugs and neural circuits of feeding." Trends in Pharmacological Sciences, 29(4):208-217. Review of monoaminergic control of appetite relevant to tesofensine's mechanism.
• Neary NM, Goldstone AP, Bloom SR. (2004) — "Appetite regulation: from the gut to the hypothalamus." Clinical Endocrinology, 60(2):153-160. Background on appetite neurobiology relevant to understanding tesofensine's central mechanism.
• Appolinario JC, Bueno JR, Coutinho W. (2004) — "Psychotropic drugs in the treatment of obesity: what promise?" CNS Drugs, 18(10):629-651. Review of centrally-acting anti-obesity agents including monoamine reuptake inhibitors.

Regulatory References

• FDA: Drug Safety Communication on Sibutramine (Meridia) Withdrawal (2010)
• FDA: Guidance for Industry — Developing Products for Weight Management (2007, updated)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.